ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates

Company Performance - ARS Pharmaceuticals, Inc. reported a quarterly loss of $0.46 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, and compared to a loss of $0.13 per share a year ago, indicating a significant decline [1] - The company posted revenues of $15.72 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.98%, and showing a substantial increase from year-ago revenues of $0.5 million [2] - Over the last four quarters, ARS Pharmaceuticals has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates two times [2] Stock Performance - ARS Pharmaceuticals shares have increased approximately 57.9% since the beginning of the year, significantly outperforming the S&P 500's gain of 9.6% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.41 on revenues of $29.98 million, and for the current fiscal year, it is -$1.44 on revenues of $84.04 million [7] Industry Outlook - The Medical - Drugs industry, to which ARS Pharmaceuticals belongs, is currently ranked in the top 34% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can materially impact stock performance [5][8]